Ruxolitinib Appears Promising as Treatment of Chronic Graft-Versus-Host Disease
Rushang D. Patel, MD, discusses the background to the single center experience with ruxolitinib as treatment of patients with chronic graft-versus-host disease.
Rushang D. Patel, MD, of Advent Health in Orlando, Florida, discusses the background to the single center experience with ruxolitinib (Jakafi) as treatment of patients with chronic graft-versus-host disease (GVHD).
There are a number of options in the second-line setting and beyond for chronic GVHD, but the response rates are not as good as clinicians hope. There is always room for better options, Patel says, and there have already been encouraging data for ruxolitinib in acute GVHD, which was approved by the FDA for the third-line setting.
While data from large clinical trials evaluating ruxolitinib in chronic GVHD are maturing, Patel shares his single center experience with ruxolitinib for chronic GVHD in this setting at the 2020 Transplantation & Cellular Therapy Meetings.
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
